Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

302
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
302
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

275
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
275
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

358
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
358
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

350
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
350
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

151
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
151
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

464
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
464

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding clinical variability in FBXW7-related neurodevelopmental disorder: a multicenter case series.

Journal of neurodevelopmental disorders·2026
Same author

Turbocharging synaptic transmission: 12 SNAREpins are required for rapid release of reconstituted synaptic vesicles.

Science advances·2026
Same author

Self-Limited Focal Epilepsies in Childhood: How Many and How to Treat.

Pediatric reports·2026
Same author

WWOX-Related Epileptic Encephalopathy (WOREE Syndrome): Clinical Case Study and Literature Review.

Current issues in molecular biology·2026
Same author

From Growth Trajectory to Functional Decline: Age-Contextualized Nutritional Strategies for Muscle Vulnerability. A Narrative Review.

Nutrients·2026
Same author

Self-limited Neonatal Epilepsy associated with global developmental delay and high-threshold sensory profile: A novel KCNQ3 de novo variant unusually located in the voltage sensor S4 segment of the Kv7.3 channel subunit.

Seizure·2026

Related Experiment Video

Updated: Jun 16, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.4K

AMPA Receptor Modulation Through Medium-Chain Triglycerides and Decanoic Acid Supports Nutritional Intervention in

Raffaele Falsaperla1, Vincenzo Sortino2,3, Miguel Angel Soler4

  • 1Department of Medical Science-Pediatrics, University of Ferrara, 44124 Ferrara, Italy.

Nutrients
|June 13, 2025
PubMed
Summary

Medium-chain triglycerides (MCTs) show promise for managing pediatric drug-resistant epilepsy (DRE) by inhibiting AMPA receptors. This review explores MCTs as an add-on to ketogenic diets and as supplementation in free diets for improved seizure control.

Keywords:
AMPAMCTsdrug-resistant epilepsyketogenic diet

More Related Videos

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays
10:24

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays

Published on: May 15, 2018

14.6K
A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

7.6K

Related Experiment Videos

Last Updated: Jun 16, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.4K
Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays
10:24

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays

Published on: May 15, 2018

14.6K
A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

7.6K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pediatric Neurology

Background:

  • Developmental epileptic encephalopathies (DEEs) often cause severe cognitive/motor impairments and refractory epilepsy unresponsive to standard medications.
  • The classic ketogenic diet (KD) is effective for some DEEs and refractory epilepsies but has high burden and low adherence.
  • Medium-chain triglycerides (MCTs), especially decanoic acid, are investigated for direct AMPA receptor inhibition and seizure reduction.

Purpose of the Study:

  • To systematically review the role of MCT add-on therapy to classic KD and MCT supplementation in free diets for pediatric drug-resistant epilepsy (DRE).
  • To explore the mechanisms of MCTs, particularly decanoic acid, in modulating AMPA receptors for seizure control.

Main Methods:

  • Systematic review of articles published between January 2000 and January 2025.
  • Focus on studies investigating MCTs in ketogenic diets and free diets for pediatric DRE.
  • Analysis of pre-clinical and clinical evidence on MCTs' impact on epileptic seizures.

Main Results:

  • MCTs, particularly decanoic acid, exert their anti-seizure effects through negative modulation of AMPA receptors.
  • Evidence suggests a positive impact of MCTs on epileptic seizures in pediatric DRE.
  • MCTs demonstrate therapeutic potential as an add-on therapy in both ketogenic and unrestricted diets.

Conclusions:

  • MCTs, especially decanoic acid, offer a promising therapeutic avenue for pediatric DRE by targeting AMPA receptors.
  • While MCTs show beneficial seizure outcomes, challenges in implementation and adherence require further research.
  • Future research should focus on optimizing MCT-based therapies for sustained seizure control in children with DRE.